-
近年来,我国甲状腺癌的发病率日益升高,女性的发病率增幅较大,目前已位居女性癌症发病率的第4位[1],其中DTC约占80%~90%[2]。目前国内外推荐的DTC的规范性治疗手段为手术切除+131I治疗+TSH抑制治疗,131I治疗已经成为DTC治疗中的重要环节。131I治疗后6个月行131I诊断性全身显像(diagnostic whole-body scan,Dx-WBS),可以评价清甲是否成功、判断DTC的复发和转移[3]。131I释放γ射线,具有很强的穿透能力,会对周围人群产生外照射。目前多是关于患者服治疗剂量131I后外部剂量当量率的研究[4],对于131I治疗后服诊断剂量患者对周围人群辐射水平的研究较少。因此,本研究通过测量患者131I治疗后行Dx-WBS期间不同时间1 m处的周围剂量当量率,评估Dx-WBS期间对周围的辐射水平,以便给予患者和周围人群提供最优化的辐射防护指导意见。
-
85例患者服诊断剂量131I后2、 24、 48 h时1 m处周围剂量当量率分别为3.20~9.66 (6.55±1.42)、0.49~4.00(1.92±0.65)和0.15~1.20(0.58±0.22) μSv/h,差异有统计学意义(F=807.30,P=0.000)。距离患者1 m处周围剂量当量率在2 h时水平较高,24 h时较之前明显降低,且在48 h时处于极低水平。
-
由表1可知,男性和女性患者在各时间点1 m处周围剂量当量率的差异均无统计学意义(t=−0.56、1.65、1.72,均 P>0.05);年龄≥55岁组患者在服131I后 24 h时1 m处周围剂量当量率高于年龄<55岁组患者,差异有统计学意义(t=2.29,P=0.02),2 h和48 h时的差异无统计学意义(t=0.89、0.62,均P>0.05);阴性组和阳性组在2、24、48 h时的1 m处周围剂量当量率差异均无统计学意义(t=1.72、1.34、0.47,均 P>0.05)。且所有患者服药后48 h时1 m处周围剂量当量率均小于WS533-2017《临床核医学患者防护要求》[6]规定的1.40 μSv/h(131I治疗甲亢和甲状腺癌患者出院后32 d距离患者1 m处的周围剂量当量率近似值为1.40 μSv/h)。
分组 例数 2 h 24 h 48 h 性别 男性 18 6.38±1.62 2.18±0.82 0.67±0.26 女性 67 6.60±1.37 1.94±0.59 0.56±0.21 年龄 ≥55岁组 18 6.82±1.19 2.00±0.69 0.61±0.24 <55岁组 67 6.48±1.47 1.83±0.58a 0.58±0.22 131I治疗效果 阴性组 48 6.78±1.51 1.99±0.65 0.59±0.24 阳性组 37 6.25±1.25 1.81±0.57 0.57±0.20 注:表中,a:与 ≥55岁组比较,差异有统计学意义(t=2.29,P=0.02)。DTC:分化型甲状腺癌 表 1 85例DTC患者131I治疗后行诊断性全身显像不同时间点组间1 m处周围剂量当量率的比较(
,μSv/h)$\scriptstyle{\bar x} \pm s $ Table 1. Comparison of ambient dose equivalent rate at 1 m at differernt time points between different groups in 85 patients after underwenting diagnostic whole-body scan (
,μSv/h)$\scriptstyle{\bar x} \pm s $
分化型甲状腺癌患者131I治疗后诊断性全身显像周围剂量当量率动态变化的研究
Study on the dynamic change in ambient dose equivalent rate in patients with differentiated thyroid carcinoma receiving diagnostic whole-body scan after 131I therapy
-
摘要:
目的 探讨分化型甲状腺癌(DTC)患者131I治疗后6个月行诊断性全身显像(Dx-WBS)期间周围剂量当量率的动态变化。 方法 选取2018年8月至2019年1月于郑州大学第一附属医院核医学科接受131I治疗的DTC患者85例,其中男性18例、女性67例,年龄(43.9±12.0)岁;≥55岁患者18例、<55岁患者67例。所有患者均空腹服用131I 148 MBq(4 mCi),2 d后行 Dx-WBS。治疗后效果为极好反应者,即131I治疗后刺激状态下甲状腺球蛋白<1 μg/L(甲状腺球蛋白抗体阴性)且影像学检查结果为阴性者(阴性组)48例,生化不全反应、结构不全反应及不确定性反应者(阳性组)37例。所有患者分别于服131I后2、24、48 h时测定距体部1 m处的周围剂量当量率,对3个时间点的1 m处周围剂量当量率进行单因素重复测量方差分析,并采用t检验对不同性别、年龄及治疗效果组之间1 m处周围剂量当量率进行比较。 结果 (1)服131I后2、24、48 h时距患者1 m处周围剂量当量率分别为(6.55±1.42)、(1.92±0.65)、(0.58±0.22) μSv/h,差异有统计学意义(F=807.30,P=0.000);距离患者1 m处周围剂量当量率随着时间的延长而下降。(2)不同性别组在服131I后 2、4、48 h时 1 m处周围剂量当量率的差异均无统计学意义;年龄≥55岁组在24 h时 1 m处周围剂量当量率高于年龄<55岁组(t=2.29,P=0.02),2 h和48 h时的差异均无统计学意义;阴性组和阳性组1 m处周围剂量当量率在各时间点的差异均无统计学意义。 结论 DTC患者131I治疗后服诊断剂量131I后 48 h时1 m处周围剂量当量率均小于WS533-2017《临床核医学患者防护要求》规定的1.40 μSv/h,达到国家规定的出门旅行要求,且不会对周围人群产生辐射损害。 Abstract:Objective To explore the dynamic change of the ambient dose equivalent rate during diagnostic whole-bady scan with differentiated thyroid carcinoma after 131I therapy 6 months. Methods This study enrolled 85 patients aged (18 males and 67 females; 43.9±12.0 years old ) with DTC who received 131I therapy in the Department of Nuclear Medicine of The First Affiliated Hospital of Zhengzhou University from August 2018 to January 2019. Among them, 18 patients were ≥55 years old and 67 patients were <55 years old. All patients were given 148 MBq (4 mCi) of 131I on an empty stomach and received diagnostic whole-body scan 2 days later. The negative group (n=48) was defined as the excellent response. The patients in this group were administered with thyroid-stimulating hormone-stimulated thyroglobulin (<1 μg/L) in the absence of structural or functional evidence of disease (and in the absence of anti-Tg antibodies). The positive group (n=37) was defined as the biochemically incomplete response, structurally incomplete response, and indeterminate response. Ambient dose equivalent rate was determined l m away from the patients at 2, 24, and 48 h after 131I administration. One-way repeated measures ANOVA was used on the three patient groups. T test was used to compare the ambient dose equivalent rate at 1 m between different groups of gender, age, and treatment effects. Results The range of ambient dose equivalent rate at 1 m at 2, 24, and 48 h was (6.55±1.42), (1.92±0.65), and (0.58±0.22) μSv/h, respectively, indicating that ambient dose equivalent rate decreased over time. The differences were statistically significant (F=807.30, P=0.000). No statistically significant difference was found in ambient dose equivalent rate at 1 m after 131I administration at any time in groups of different genders. The ambient dose equivalent rate at 1 m at 24 h was higher in the ≥55 age group than in the <55 age group (t=2.29, P=0.02), and the other two time points were not statistically significant. No statistically significant difference was found between the negative group and the positive group at each time point. Conclusions The ambient dose equivalent rate of patients with DTC after 131I treatment who received the diagnostic dose of 131I for 48 h was less than 1.40 μSv/h (the 2017 clinical nuclear medicine patient protection requirements, WS 533-2017). Thus, no restrictions for the patients to travel should be imposed as they do not exert harmful radiation on others. -
表 1 85例DTC患者131I治疗后行诊断性全身显像不同时间点组间1 m处周围剂量当量率的比较(
,μSv/h)$\scriptstyle{\bar x} \pm s $ Table 1. Comparison of ambient dose equivalent rate at 1 m at differernt time points between different groups in 85 patients after underwenting diagnostic whole-body scan (
,μSv/h)$\scriptstyle{\bar x} \pm s $ 分组 例数 2 h 24 h 48 h 性别 男性 18 6.38±1.62 2.18±0.82 0.67±0.26 女性 67 6.60±1.37 1.94±0.59 0.56±0.21 年龄 ≥55岁组 18 6.82±1.19 2.00±0.69 0.61±0.24 <55岁组 67 6.48±1.47 1.83±0.58a 0.58±0.22 131I治疗效果 阴性组 48 6.78±1.51 1.99±0.65 0.59±0.24 阳性组 37 6.25±1.25 1.81±0.57 0.57±0.20 注:表中,a:与 ≥55岁组比较,差异有统计学意义(t=2.29,P=0.02)。DTC:分化型甲状腺癌 -
[1] 陈万青, 李贺, 孙可欣, 等. 2014年中国恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志, 2018, 40(1): 5−13. DOI: 10.3760/cma.j.issn.0253−3766.2018.01.002.
Chen WQ, Li H, Sun KX, et al. Report of Cancer Incidence and Mortality in China, 2014[J]. Chin J Oncol, 2018, 40(1): 5−13. DOI: 10.3760/cma.j.issn.0253−3766.2018.01.002.[2] Heston TF, Wahl RL. Molecular imaging in thyroid cancer[J]. Cancer Imaging, 2010, 10(1): 1−7. DOI: 10.1102/1470−7330.2010.0002. [3] 中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4): 264−278. DOI: 10.3760/cma.j.issn.2095−2848.2014.04.002.
Chinese Society of Nuclear Medicine. Clinical guidelines for 131I therapy of differentiated thyroid cancer (2014)[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4): 264−278. DOI: 10.3760/cma.j.issn.2095−2848.2014.04.002.[4] 吉倩婧, 底瑞青, 陈伟娜, 等. 机器人用于分化型甲状腺癌术后131 I治疗住院患者体内残留放射性活度测定的研究[J]. 中华核医学与分子影像杂志, 2019, 39(10): 601−605. DOI: 10.3760/cma.j.issn.2095−2848.2019.10.006.
Ji QJ, Di RQ, Chen WN, et al. Measurement of residual radioactivity in postoperative inpatients with differentiated thyroid carcinoma after 131 I treatment using robot[J]. Chin J Nucl Med Mol Imaging, 2019, 39(10): 601−605. DOI: 10.3760/cma.j.issn.2095−2848.2019.10.006.[5] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1−133. DOI: 10.1089/thy.2015.0020. [6] 中华人民共和国国家卫生和计划生育委员会. WS 533-2017临床核医学患者防护要求[S]. 北京: 中国标准出版社, 2017.
The State Health and Family Planning Commission of the People's Republic of China. WS 533-2017 Requirements for patient radiation protection in nuclear medicine[S]. Beijing: Standards Press of China, 2017.[7] Kogai T, Brent GA. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics[J]. Pharmacol Ther, 2012, 135(3): 355−370. DOI: 10.1016/j.pharmthera.2012.06.007. [8] Bartlett ML. Estimated dose from diagnostic nuclear medicine patients to people outside the Nuclear Medicine department[J]. Radiat Prot Dosimetry, 2013, 157(1): 44−52. DOI: 10.1093/rpd/nct119. [9] 汤敏敏, 刘建中, 武志芳, 等. 分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J]. 中华放射医学与防护杂志, 2015, 35(4): 299-302. DOI: 10.3760/cma.j.issn.0254−5098.2015.04.016.
Tang MM, Liu JZ, Wu ZF, et al. Estimation of residual activity in patients with differentiated thyroid cancer after administration of 131I for therapy[J].Chin J Radiol Med Prot, 2015, 35(4): 299-302. DOI: 10.3760/cma.j.issn.0254−5098.2015.04.016.[10] 袁海娟, 林主戈, 吴春兴, 等. 131I治疗分化型甲状腺癌患者体内残留辐射剂量及病房辐射剂量的监测分析[J]. 国际放射医学核医学杂志, 2019, 43(5): 400−404. DOI: 10.3760/cma.j.issn.1673−4114.2019.05.003.
Yuan HJ, Lin ZG, Wu CX, et al. Radiation monitoring in patients with differentiated thyroid carcinoma treated with iodine-131 and their wards[J]. Int J Radiat Med Nucl Med, 2019, 43(5): 400−404. DOI: 10.3760/cma.j.issn.1673−4114.2019.05.003.[11] 康增寿, 李方, 林岩松. 开放性放射性核素治疗后患者免住院的建议(ICRP94报告要点解读)[J]. 国际放射医学核医学杂志, 2019, 43(5): 397−399. DOI: 10.3760/cma.j.issn.1673−4114.2019.05.002.
Kang ZS, Li F, Lin YS. Release of patients therapy with unsealed radionuclides (ICRP publication 94)[J]. Int J Radiat Med Nucl Med, 2019, 43(5): 397−399. DOI: 10.3760/cma.j.issn.1673−4114.2019.05.002.[12] Wang B, Katsube T, Begum N, et al. Revisiting the health effects of psychological stress-its influence on susceptibility to ionizing radiation: a mini-review[J]. J Radiat Res, 2016, 57(4): 325−335. DOI: 10.1093/jrr/rrw035. [13] Rosenthal MS. Patient Misconceptions and ethical challenges in radioactive iodine scanning and therapy[J]. J Nucl Med Technol, 2006, 34(3): 143−150. [14] 史文杰, 汪小龙, 王月英. 浅谈放射性核素治疗病房的建设与管理[J]. 国际放射医学核医学杂志, 2019, 43(5): 411−415. DOI: 10.3760/cma.j.issn.1673−4114.2019.05.005.
Shi WJ, Wang XL, Wang YY. Building and management of the radionuclide treatment ward[J]. Int J Radiat Med Nucl Med, 2019, 43(5): 411−415. DOI: 10.3760/cma.j.issn.1673−4114.2019.05.005.